Navigation Links
GlaxoSmithKline Donates Scientific Equipment to Advance IDRI's Global Health Mission
Date:10/3/2011

SEATTLE, Oct. 3, 2011 /PRNewswire-USNewswire/ -- The Infectious Disease Research Institute (IDRI) announces today that GlaxoSmithKline (GSK) Biologicals Hamilton has donated a broad range of instrumentation and equipment that will assist IDRI as it designs and validates solutions to reduce the burden of disease in the developing world. IDRI will apply the gift as it prepares for clinical trials in the areas of tuberculosis, leishmaniasis, malaria, leprosy, and pandemic influenza.

"We at IDRI view this generous gift by our friends at GSK as a demonstration of confidence that the products IDRI is researching today will soon be making a difference for people worldwide," said H. Stewart Parker, IDRI's Chief Executive Officer.  "GSK's generous donation will enable new health technologies to be deployed for a number of diseases that particularly affect those in low resource settings."

"GSK has seen IDRI's talented scientists develop world-class technologies that have entered into numerous successful clinical trials," said Pamela Sager, Business Support Manager at GSK.  "We believe that the equipment we are giving to IDRI will not only further the world's scientific understanding of infectious diseases, but that this gift will also advance IDRI's global health mission."

GSK acquired the equipment when the company purchased the former Corixa site in Seattle in 2005.

About IDRI
IDRI is a Seattle-based not-for-profit organization committed to applying innovative science to the research and development of products to prevent, detect, and treat infectious diseases of poverty. By integrating capabilities — including early stage drug discovery, preclinical testing, manufacturing, and clinical trials — IDRI strives to create an efficient pathway bringing scientific innovation from the laboratory to the people who need it most.

For more information, go to www.idri.org.
IDRI Contact: media@idri.org, 206-381-0883

About GSK
GlaxoSmithKline:  A Leader in Vaccines
GlaxoSmithKline Biologicals (GSK Biologicals), GlaxoSmithKline's vaccines business, is one of the world's leading vaccine companies and a leader in innovation.   The company is active in the fields of vaccine research, development and production with over 30 vaccines approved for marketing around the world and 20 more in development.

For more information, go to www.gsk.com.


'/>"/>
SOURCE Infectious Disease Research Institute (IDRI)
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. GlaxoSmithKline CEO and CFO Interviewed on Q2 2011 Results
2. GlaxoSmithKline Receives FDA Approval for BOOSTRIX® to Help Prevent Whooping Cough in Adults 65 Years and Older
3. GlaxoSmithKline Implements Next Phase of New Incentive Compensation Program for U.S. Sales Representatives
4. GlaxoSmithKline Confirms allis Safety Profile
5. Tolerx and GlaxoSmithKline Announce Phase 3 Defend-1 Study of Otelixizumab in Type 1 Diabetes Did Not Meet Its Primary Endpoint
6. GlaxoSmithKline Wins Environmental Stewardship Award
7. GlaxoSmithKline 15th Annual IMPACT Awards Seek Philadelphia Area and Camden Healthcare Nonprofits
8. GlaxoSmithKline Applauds North Carolinas Child Advocates
9. A Statement from GlaxoSmithKline Consumer Healthcare on FDA Regulation of Smokeless Tobacco Products
10. Mylan Granted Temporary Restraining Order Against GlaxoSmithKline and Apotex Prohibiting the Supply, Sale and/or Importing of a Generic Version of Paxil CR
11. GlaxoSmithKline CEO Interviewed On Half-Year and Q2 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Research ... Devices Global Market - Forecast to 2022" report to ... the treatment method for the patients with kidney failure, it ... excess fluid from the patient,s blood and thus the treatment ... potassium and chloride in balance. Increasing number ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
(Date:6/23/2016)... , June 23, 2016 Bracket , a ... its next generation clinical outcomes platform, Bracket eCOA (SM) ... on June 26 – 30, 2016 in Philadelphia ... electronic Clinical Outcome Assessment product of its kind to fully ... Bracket eCOA 6.0 is a flexible platform for ...
Breaking Medicine Technology:
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... On June ... sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, ... of the city’s history as home to some of the world’s leading providers of ...
(Date:6/25/2016)... D.C. (PRWEB) , ... June 25, 2016 , ... ... discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, ... their work on several important health care topics including advance care planning, healthcare ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may suffer ... unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid ... healthy coping following a traumatic event. , Trauma sufferers tend to feel a range ...
(Date:6/24/2016)... San Francisco, CA (PRWEB) , ... June 24, ... ... at CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has ... , self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , ...
Breaking Medicine News(10 mins):